References
- AIFA. (2022). Official list of innovative oncological drugs (as of October 2022). https://www.aifa.gov.it/farmaci-innovativi.
- AIOM. (2022). I numeri del cancro in Italia. https://www.aiom.it/wp-content/uploads/2022/12/2022_AIOM_NDC-web.pdf.
- Albin, N., Chassagnol, F., & Bergmann, J. F. (2019). Early access to health products in France: Major advances of the French “conseil stratégique des industries de santé” (CSIS) to be implemented (modalities, regulations, funding). Therapies, 74(1), 103–117. https://doi.org/10.1016/j.therap.2018.12.002
- André, T., Shiu, K. K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., de la Fouchardiere, C., Rivera, F., Elez, E., Bendell, J., Le, D. T., Yoshino, T., Van Cutsem, E., Yang, P., Farooqui, M. Z. H., … Diaz, L. A. (2020). Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. New England Journal of Medicine, 383(23), 2207–2218. https://doi.org/10.1056/NEJMoa2017699
- Arksey, H., & O'Malley, L. (2005). Scoping studies: Towards a methodological framework. International Journal of Social Research Methodology, 8(1), 19–32. https://doi.org/10.1080/1364557032000119616
- BfArM. (2024). Compassionate use programmes. German Federal Institute for Drugs and Medical Devices. Retrieved June 2, 2024, from https://www.bfarm.de/EN/Medicinal-products/Clinical-trials/Compassionate-Use/_node.html.
- Buja, A., Rivera, M., De Polo, A., Brino, E. D., Marchetti, M., Scioni, M., Pasello, G., Bortolami, A., Rebba, V., Schiavon, M., Calabrese, F., Mandoliti, G., Baldo, V., & Conte, P. (2021). Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model. Thoracic Cancer, 12(1), 13–20. https://doi.org/10.1111/1759-7714.13616
- CEPS. (2021). Rapport d’activitè 2020. https://sante.gouv.fr/ministere/acteurs/instances-rattachees/comite-economique-des-produits-de-sante-ceps/article/rapports-d-activite-du-ceps.
- Chu, C., Barbou des Courières, S., Fournier, K., Kelley, S., Bay, J. O., & Gadeyne, M. (2022). Réforme de l'accès dérogatoire aux médicaments [Reform of early access to medicinal products in France]. Bulletin du Cancer, 109(1), 20–22. https://doi.org/10.1016/j.bulcan.2021.11.008
- Colombo, G. L., Cammà, C., Attili, A. F., Ganga, R., Gaeta, G. B., Brancaccio, G., Franzini, J. M., Volpe, M., & Turchetti, G. (2015). Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers. Therapeutics and Clinical Risk Management, 11, 1603–1612. https://doi.org/10.2147/tcrm.S88208
- Crocetti, E., Gori, S., & Falcini, F. (2018). Metastatic breast cancers: Estimates for Italy. Tumori Journal, 104(2), 116–120. https://doi.org/10.1177/0300891618766177
- Degrassat-Théas, A., Bocquet, F., Sinègre, M., Peigné, J., & Paubel, P. (2015). The “temporary recommendations for Use”: A dual-purpose regulatory framework for off-label drug use in France. Health Policy, 119(11), 1399–1405. https://doi.org/10.1016/j.healthpol.2015.09.003
- Doyle, S. (2007). Member checking with older women: A framework for negotiating meaning. Health Care for Women International, 28(10), 888–908. https://doi.org/10.1080/07399330701615325
- Eichler, H. G., Pignatti, F., Flamion, B., Leufkens, H., & Breckenridge, A. (2008). Balancing early market access to new drugs with the need for benefit/risk data: A mounting dilemma. Nature Reviews Drug Discovery, 7(10), 818–826. https://doi.org/10.1038/nrd2664
- Facchinetti, F., Pilotto, S., Metro, G., Baldini, E., Bertolaccini, L., Cappuzzo, F., Delmonte, A., Gasparini, S., Inno, A., Marchetti, A., Passiglia, F., Puma, F., Ricardi, U., Rossi, A., Crinò, L., & Novello, S. (2019). Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). Tumori Journal, 105(5_suppl), 3–14. https://doi.org/10.1177/0300891619857418
- Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T. Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., Li, D., Verret, W., Xu, D. Z., Hernandez, S., Liu, J., Huang, C., Mulla, S., Wang, Y., Lim, H. Y., … Cheng, A. L. (2020). Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. New England Journal of Medicine, 382(20), 1894–1905. https://doi.org/10.1056/NEJMoa1915745
- Francisci, S., Guzzinati, S., Mezzetti, M., Crocetti, E., Giusti, F., Miccinesi, G., Paci, E., Angiolini, C., & Gigli, A. (2013). Cost profiles of colorectal cancer patients in Italy based on individual patterns of care. BMC Cancer, 13(1), 329. https://doi.org/10.1186/1471-2407-13-329
- GKV-SV. (2022a). Bundesministerium der Justiz. Sozialgesetzbuch (SGB) Fünftes Buch (V) - Gesetzliche Krankenversicherung - (Artikel 1 des Gesetzes v. 20. Dezember 1988, BGBl. I S. 2477) § 35a Bewertung des Nutzens von Arzneimitteln mit neuen Wirkstoffen, Verordnungsermächtigung. https://www.gesetze-im-internet.de/sgb_5/__35a.html.
- GKV-SV. (2022b). Bundesministerium der Justiz. Sozialgesetzbuch (SGB) Fünftes Buch (V) - Gesetzliche Krankenversicherung - (Artikel 1 des Gesetzes v. 20. Dezember 1988, BGBl. I S. 2477) § 130b Vereinbarungen zwischen dem Spitzenverband Bund der Krankenkassen und pharmazeutischen Unternehmern über Erstattungsbeträge für Arzneimittel, Verordnungsermächtigung.
- GKV-SV. (2022c). Spitzenverband Bund der Krankenkassen (GKV-SV). Übersicht zu den Verhandlungen der Erstattungsbeträge nach § 130b SGB V 2022. https://www.gkv-spitzenverband.de/krankenversicherung/arzneimittel/verhandlungen_nach_amnog/ebv_130b/ebv_nach_130b.jsp;jsessionid = EE9C0B0E70012C6376E08A908004EAF8?submitted = true&sort = dateUpdate&descending = 0&searchterm = Suchbegriff+eingeben&status = Alle&specialFeature = &additionalInformation = &priceStructureModel = .
- Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S. C., Manso, L., Freedman, O. C., Garnica Jaliffe, G., Forrester, T., Frenzel, M., Barriga, S., Smith, I. C., Bourayou, N., & Di Leo, A. (2017). MONARCH 3: Abemaciclib As initial therapy for advanced breast cancer. Journal of Clinical Oncology, 35(32), 3638–3646. https://doi.org/10.1200/jco.2017.75.6155
- Guest, G., & MacQueen, K. (2008, January 1). Handbook for team-based qualitative research. AltaMira Press.
- HAS. (2021). Autorisation d’accès précoce aux médicaments: doctrine d’évaluation de la HAS. https://www.has-sante.fr/upload/docs/application/pdf/2021-06/acces_precoces_-_doctrine.pdf
- HAS. (2022). Autorisation de mise sur le marché. Autorisation d’accès précoce, autorisation d’accès compassionnel et cadre de prescription compassionnelle. https://sante.gouv.fr/soins-et-maladies/medicaments/professionnels-de-sante/autorisation-de-mise-sur-le-marche/article/autorisation-d-acces-precoce-autorisation-d-acces-compassionnel-et-cadre-de
- IQWiG. (2022). Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Arzneimittel-Zulassung und frühe Nutzenbewertung in Deutschland. https://www.iqwig.de/presse/im-fokus/neue-arzneimittel-zulassung-nutzenbewertung-erstattung/1-arzneimittel-zulassung-und-fruehe-nutzenbewertung-in-deutschland/
- Martinalbo, J., Bowen, D., Camarero, J., Chapelin, M., Démolis, P., Foggi, P., Jonsson, B., Llinares, J., Moreau, A., O'Connor, D., Oliveira, J., Vamvakas, S., & Pignatti, F. (2016). Early market access of cancer drugs in the EU. Annals of Oncology, 27(1), 96–105. https://doi.org/10.1093/annonc/mdv506
- Masini, C., Gallegati, D., Gentili, N., Massa, I., Ciucci, R., & Altini, M. (2021). The challenge of sustainability of high-cost oncological drugs: A budgeting model in an Italian cancer center. International Journal of Environmental Research and Public Health, 18(24): 13413. https://doi.org/10.3390/ijerph182413413
- Mennini, F. S., Trabucco Aurilio, M., Gazzillo, S., Nardone, C., Sciattella, P., Marcellusi, A., Migliorini, R., Sciannamea, V., Piccioni, A., Bolcato, M., & Barni, S. (2021). An analysis of the social and economic costs of breast cancer in Italy. International Journal of Environmental Research and Public Health, 18(17): p. 9005. https://doi.org/10.3390/ijerph18179005
- Montilla, S., Alessi, E., Gallo, V., Petrelli, M., Trapanese, M., Melchionda, R., & Rapone, L. (2022). Rapporto sulle tempistiche delle procedure di prezzo e rimborso dei farmaci nel quinquennio 2018-2021. https://www.aifa.gov.it/-/rapporto-sulle-tempistiche-delle-procedure-di-prezzo-e-rimborso-dei-farmaci-nel-quinquennio-2018-2022.
- NAACCR. (2019). Cancer in North America: 2012-2016. https://www.naaccr.org/wp-content/uploads/2019/05/CINA2018.v3.mortality.pdf.
- Newton, M., Stoddart, K., Travaglio, M., & Troein, P. (2023). EFPIA Patients W.A.I.T. Indicator 2022 Survey. https://www.efpia.eu/media/676539/efpia-patient-wait-indicator_update-july-2022_final.pdf.
- O'Brien, B. C., Harris, I. B., Beckman, T. J., Reed, D. A., & Cook, D. A. (2014). Standards for reporting qualitative research: A synthesis of recommendations. Academic Medicine, 89(9), 1245–1251. https://doi.org/10.1097/acm.0000000000000388
- Pang, H., Wang, M., Kiff, C., Soni, M., Stein, D., & Tyas, D. (2019). Early access to medicines scheme: Real-world data collection. Drug Discovery Today, 24(12), 2231–2233. https://doi.org/10.1016/j.drudis.2019.06.009
- Panteli, D., Arickx, F., Cleemput, I., Dedet, G., Eckhardt, H., Fogarty, E., Gerkens, S., Henschke, C., Hislop, J., Jommi, C., Kaitelidou, D., Kawalec, P., Keskimaki, I., Kroneman, M., Lopez Bastida, J., Pita Barros, P., Ramsberg, J., Schneider, P., Spillane, S., … Busse, R. (2016). Pharmaceutical regulation in 15 European countries review. Health Systems in Transition, 18(5), 1–122.
- Schilsky, R. L., Nass, S., Le Beau, M. M., & Benz, Jr E. J. (2020). Progress in cancer research, prevention, and care. New England Journal of Medicine, 383(10), 897–900. https://doi.org/10.1056/NEJMp2007839
- Schleich, W., Vollmer, L., Prada, M., Berard, I., Benazet, F., Brosa, M., & Forsyth, C. (2019). PRO80 comparison of early access programmes for orphan drugs in the EU-5 countries. Value in Health, 22, S855–S856. https://doi.org/10.1016/j.jval.2019.09.2410
- Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C., Cho, B. C., Cheng, Y., Cho, E. K., Voon, P. J., Planchard, D., Su, W. C., Gray, J. E., … Ramalingam, S. S. (2018). Osimertinib in untreated EGFR-mutated advanced Non-small-cell lung cancer. New England Journal of Medicine, 378(2), 113–125. https://doi.org/10.1056/NEJMoa1713137
- Tarantola, A., Otto, M. H., Armeni, P., Costa, F., Malandrini, F., & Jommi, C. (2023). Early access programs for medicines: Comparative analysis among France, Italy, Spain, and UK and focus on the Italian case. Journal of Pharmaceutical Policy and Practice, 16(1), 67. https://doi.org/10.1186/s40545-023-00570-z
- White, L. A., Menzin, J., Korn, J. R., Friedman, M., Lang, K., & Ray, S. (2012). Medical care costs and survival associated with hepatocellular carcinoma among the elderly. Clinical Gastroenterology and Hepatology, 10(5), 547–554. https://doi.org/10.1016/j.cgh.2011.12.031